Skip to main content

Table 7 Factors associated with poor TTR among patients receiving warfarin therapy

From: Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study

Variable

TTR ≥ 65%

TTR < 65%

COR (95%CI)

AOR (95%CI)

P-value

Treatment group

 UMC

111(21.1)

239(45.5)

1.00

1.00

0.01*

 PLAC

73(13.9)

102(19.4)

0.65(0.45,0.95)

0.57(0.36,0.88)

 

Sex

 Female

132(25.1)

243(46.3)

1.00

1.00

0.79

 Male

52(9.9)

98(18.7)

1.02(0.69,1.52)

0.95(0.62,1.44)

 

Age in years

 

 18–30

32(6.1)

75(14.3)

1.00

1.00

 

 31–45

81(15.4)

150(28.6)

0.79(0.48,1.29)

0.79(0.47,1.32)

0.36

 46–64

53(10.1)

82(15.6)

0.66(0.39,1.13)

0.57(0.32,1.02)

0.06

 ≥ 65

18(3.4)

34(6.5)

0.81(0.39,1.63)

0.45(0.19,1.03)

0.06

HAS-BLED risk scores

 No risk

65(12.4)

125(23.8)

1.00

1.00

 

 Low risk

46(8.8)

34(6.5)

0.38(0.23, 0.66)

0.51(0.29,0.91)

0.02*

 Moderate risk

65(12.4)

153(29.1)

1.22(0.81,1.86)

1.68(1.07,2.64)

0.03*

 High risk

8(1.5)

29(5.5)

1.89(0.82,4.36)

3.08(1.17,8.09)

0.02*

Post-mechanical heart valves

 No

163(31.0)

278(53.0)

1.00

1.00

0.01*

 Yes

21(4.0)

63(12.0)

1.76(1.04,2.99)

2.11(1.17,3.81)

 

Post PMTC valvotomy

 No

169(32.2)

329(62.7)

1.00

1.00

0.09

 Yes

15(2.9)

12(2.3)

0.41(0.19,0.89)

0.49(0.22,1.13)

 

INR monitoring interval

  

0.99(0.98,1.01)

0.98(0.97,0.99)

0.002*